4-<2-(1-imidazolyl)ethyl>pyridine | 103095-54-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-<2-(1-imidazolyl)ethyl>pyridine
• 英文别名: 4-(2-imidazol-1-yl-ethyl)-pyridine；1-(β--ethyl)-imidazol；1(β--ethyl)-imidazol；1-<2-(4-Pyridyl)-ethyl>-imidazol；Pyridine, 4-[2-(1H-imidazol-1-yl)ethyl]-；4-(2-imidazol-1-ylethyl)pyridine
• CAS: 103095-54-1
• 化学式: C₁₀H₁₁N₃
• mdl: MFCD00957200
• 分子量: 173.217
• InChiKey: JFBPQDAJCGEDKW-UHFFFAOYSA-N

物化性质

• 熔点：
  88-90 °C
• 沸点：
  184-186 °C(Press: 1 Torr)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-<2-(1-imidazolyl)ethyl>pyridine 在 potassium carbonate 作用下， 以 水 、 丙酮 、 苯 为溶剂， 反应 64.0h， 生成 1-methyl-4-vinylpyridinium iodide
  参考文献：
  名称：

  Katritzky, Alan R.; Khan, Ghulam R.; Marson, Charles M., Journal of Heterocyclic Chemistry, 1987, vol. 24, p. 641 - 644

  摘要：

  DOI：
• 作为产物：
  描述：

  咪唑 、 alkaline earth salt of/the/ methylsulfuric acid 反应 3.0h， 生成 4-<2-(1-imidazolyl)ethyl>pyridine
  参考文献：
  名称：

  Substituted heteroaromatic compounds: effect on nicotine self-administration in rats

  摘要：

  Certain compounds that nonselectively inhibit a prominent human nicotine-metabolizing enzyme (i.e., human cytochrome P-450 2A6, hCYP 2A6) showed inhibition of smoking in humans. However, a comprehensive examination of hCYP 2A6 inhibitors to decrease nicotine self-administration in rats has not been reported.We tested substituted heteroaromatic compounds designed to selectively inhibit hCYP 2A6 in a model system to (a) examine selective hCYP 2A6 inhibitors to decrease cotinine formation in vivo in rats administered with nicotine and (b) examine their efficacy to decrease nicotine self-administration in rats.Rats were trained to IV self-administer nicotine in 1-h sessions. Nicotine self-administration was carried out at a unit dose of 0.03 mg/kg/infusion in 0.1 ml/s. Pretreatment with substituted heteroaromatic test compounds (0.5-25 mg/kg, i.p., 30 min prior to nicotine self-administration sessions) resulted in dose-dependent decreases of nicotine self-administration. Using operant conditioning techniques, nicotine- vs. food-reinforced responding was evaluated for compounds 10 and 11.Compounds 10 and 11 selectively decreased nicotine self-administration with estimated ED50 values 4 and 2.8 mg/kg, respectively. Of the test compounds examined, none showed significant affinity for mammalian alpha 4 beta 2- or alpha 7-neuronal nicotinic acetylcholine (nAChR) receptors and none were inhibitors of the human dopamine transporter (hDAT); thus, neither the endogenous nAChRs nor DAT apparently plays a role in decreasing nicotine self-administration for this series of compounds.The results indicate that chemical analogs of nicotine can play a role in nicotine self-administration harm reduction but a non-nAChR and a non-hDAT mechanism are likely involved.

  DOI：

  10.1007/s00213-011-2608-6

文献信息

• KATRITZKY, A. R.;KHAN, C. R.;MARSON, C. -M., J. HETEROCYCL. CHEM., 24,(1987) N 3, 641-644
  作者：KATRITZKY, A. R.、KHAN, C. R.、MARSON, C. -M.

  DOI：——

  日期：——
• SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION
  申请人：CASHMAN John R.

  公开号：US20120196905A1

  公开（公告）日：2012-08-02

  Methods and small molecule compounds for smoking and CNS disease harm reduction are provided. One example of a class of compounds that may be used is represented by the compound having the structure IA or IB in the form of free base or a pharmaceutically acceptable salt, hydrate or solvate thereof:
• US4925851A
  申请人：——

  公开号：US4925851A

  公开（公告）日：1990-05-15
• US8906943B2
  申请人：——

  公开号：US8906943B2

  公开（公告）日：2014-12-09
• [EN] SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION<br/>[FR] COMPOSÉS SYNTHÉTIQUES ET PROCÉDÉS POUR DIMINUER L'AUTO-ADMINISTRATION DE NICOTINE
  申请人：HUMAN BIOMOLECULAR RES INST

  公开号：WO2012019093A1

  公开（公告）日：2012-02-09

  Methods and small molecule compounds for smoking and CNS disease harm reduction are provided. One example of a class of compounds that may be used is represented by the compound having the structure IA or IB in the form of free base or a pharmaceutically acceptable salt, hydrate or solvate thereof:

表征谱图